Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| Akari Therapeutics plcAKTX · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 4 of 14 inputs computable; 7 are required |
| Reliability | 0.83 AUCfailure model, filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| Peer failure rate | 1.07% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | $12.5M to $120M assetstotal assets $47.9M[1] |
| Warnings | dilution, late filer, thin datanot computable: degenerate inputs, distress, fortress balance sheet |
| Inputs computable | 4 of 14 |
| Graded from | filings received through Mar 30, 2026193 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $8.572026-10-07; market equity $1.3T; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 30, 2026; the document on sec.gov.
are an oncology company developing next-generation antibody-drug conjugates (“ADCs”) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Our lead payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth.
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 32.8 | |||||||
| Gross profitability | not computable | 32.2% | |||||
| one or more required annual facts are missing | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | (13.7%) | [1,4-6] | (6.6%) | 32.8 | 811 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| five annual gross margins are required; found 0 | |||||||
| Solvency, sleeve percentile 84.2 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| latest liabilities, cash plus short-term investments, book equity, and shares are required | |||||||
| Altman Z double-prime | (19.86) | [1,7-12] | (0.31) | 73.5 | 756 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| one or more required annual facts are missing | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| interest expense must exceed $100,000 | |||||||
| Current ratio | 0.44x | [7-8] | 2.96x | 95.0 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 78.7 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| four annual observations are required; found 0 | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| four consecutive annual FCF observations are required; found 2 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| NOPAT must exceed $100,000 | |||||||
| Asset growth, three years | not computable | 2.1% | |||||
| four consecutive annual observations are required | |||||||
| Net share issuance, one year | 58.5% | [2-3] | 2.5% | 78.7 | 634 | 2026-03-01 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-07 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (74.2%) | 8.0% | 5 | hotter than 5 of 100 peers |
| Distance from 52-week high | (80.1%) | (31.4%) | 8 | closer to its high than 8 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | required accounting or market input is missing | |
| Free cash flow yield | (0.00%) | (1.0%) | 54 | pricier than 46 of 100 peers |
| Book value to price | 0.00 | 0.28 | 12 | pricier than 88 of 100 peers |
| Sales to price | not computable | 0.31 | required accounting or market input is missing | |
| Composite equity issuance, five years | not computable | 20.3% | a share count from five years earlier is required | |
| Relative strength against the sector, log excess return | (1.57) | (0.14) | 5 | ahead of 5 of 100 peers |
Inputs: market equity $1.3T; EBIT -$17.3M; free cash flow -$5.0M; book equity $18.6M; cash $7.7M[13].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | (34.2%) | ✗ fail[4,6] |
| Operating cash flow above zero | -$10.6M | ✗ fail[5] |
| Return on assets improved | 420.2 pts | ✓ pass[4,6,14-15] |
| Operating cash flow exceeds net income | $6.7M | ✓ pass[4-5] |
| Long-term leverage fell | n/a[1,6,15] | |
| Current ratio improved | 29.4 pts | ✓ pass[7-8,16-17] |
| No new shares issued | 58.5% | ✗ fail[2-3] |
| Gross margin improved | n/a | |
| Asset turnover improved | n/a[6,15] | |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $7.7M[18] |
| Operating cash flow, four quarters | -$10.8M[5,18-22] |
| Months of runway | 8.6 |
| Late filings, two years | 3 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 57 |
| 10-Q received Aug 13, 2026 | |
| Median daily dollar volume | $446,096 |
| 63 sessions | |
| Days since newest grade input | 193 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $47.9M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 2 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 91,567,009,533 | 2026-03-01 | 2026-03-30 | 10-K | filing · viewer · series |
| 3 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 57,752,981,523 | 2025-03-31 | 2025-04-15 | 10-K | filing · viewer · series |
| 4 | net income | us-gaap:NetIncomeLoss | -$17.3M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$10.6M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 6 | assets | us-gaap:Assets | $50.6M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 7 | current assets | us-gaap:AssetsCurrent | $5.5M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 8 | current liabilities | us-gaap:LiabilitiesCurrent | $12.4M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 9 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$264.6M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 10 | operating income | us-gaap:OperatingIncomeLoss | -$17.3M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 11 | book equity | us-gaap:StockholdersEquity | $28.3M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 12 | liabilities | us-gaap:Liabilities | $19.6M | 2025-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 13 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 155,758,529,533 | 2026-08-13 | 2026-08-13 | 10-Q | filing · viewer · series |
| 14 | net income | us-gaap:NetIncomeLoss | -$19.8M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 15 | assets | us-gaap:Assets | $4.4M | 2023-12-31 | 2025-04-15 | 10-K | filing · viewer · series |
| 16 | current assets | us-gaap:AssetsCurrent | $3.0M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 17 | current liabilities | us-gaap:LiabilitiesCurrent | $19.9M | 2024-12-31 | 2026-03-30 | 10-K | filing · viewer · series |
| 18 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $7.7M | 2026-06-30 | 2026-08-13 | 10-Q | filing · viewer · series |
| 19 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$5.6M | 2026-06-30 | 2026-08-13 | 10-Q | filing · viewer · series |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$2.5M | 2026-03-31 | 2026-05-19 | 10-Q | filing · viewer · series |
| 21 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$7.5M | 2025-09-30 | 2025-11-13 | 10-Q | filing · viewer · series |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$5.4M | 2025-06-30 | 2026-08-13 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.